Cordlife Group's Cellular Therapy Accreditation Suspended Indefinitely
Background
On Thursday, August 15, 2023, Cordlife Group (CGL) announced that the Foundation for the Accreditation of Cellular Therapy (FACT) had indefinitely suspended the cellular therapy accreditation of its Singapore facility.
FACT is an international organization that accredits cellular therapy facilities based on their adherence to quality and safety standards.
Impact on Cordlife's Operations
The suspension of accreditation will not affect the storage of cord blood units at Cordlife's Singapore facility.
CGL is working closely with FACT to address the issues that led to the suspension and expects to regain accreditation in due course.
The company's other facilities in Hong Kong and India are not affected by the suspension.
Reasons for Suspension
FACT has not publicly disclosed the specific reasons for the suspension.
However, CGL stated that the suspension is related to "certain operational issues" at the Singapore facility.
Next Steps
CGL is conducting a comprehensive review of its operations to identify and address the issues that led to the suspension.
The company will also work with FACT to develop a corrective action plan to regain accreditation.
Conclusion
The indefinite suspension of FACT accreditation by Cordlife Group is a significant development that has raised concerns among its customers and the wider public.
CGL is working closely with FACT to address the issues that led to the suspension and expects to regain accreditation in due course.
Comments